A multicenter randomized controlled clinical study of Qishao Tianxin prescription in the treatment of early urinary incontinence after radical prostatectomy for prostate cancer.

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100043786

Enrollment

Unknown

Registered

2021-02-28

Start date

2021-02-22

Completion date

Unknown

Last updated

2021-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary incontinence

Interventions

The experimental group:Qishao Tianxin prescription+pelvic floor muscle training

The control group:Placebo (including 1% Qishao Tianxin prescriptions)+pelvic floor muscle training

Eligibility

Sex/Gender

All

Age

55 Years to 75 Years

Inclusion criteria

Inclusion criteria: From January 2020 to June 2023, patients aged 55-75 who are prepared for radical resection of prostate cancer are mainly middle-to-high-risk prostate cancer patients: (1) PSA >= 10; Or 4= T2 stage; (3) Gleason score >= 7 points;Or the puncture Gleason score of both lobes >= 6 points at the same time; informed and agreed to participate in the clinical trial; able to cooperate with the treatment and complete the follow-up.

Exclusion criteria

Exclusion criteria: Patients with heart, brain and lung diseases or liver and renal insufficiency.

Design outcomes

Primary

Measure	Time frame
Qmax;Residual urine;	—

Secondary

Measure	Time frame
prostate-specific antigen;urine routines;OABSS;Urinary Incontinence Quality of Life Questionnaire;ICS-Q-SF;One hour urine pad test;	—

Countries

China

Contacts

Public ContactJianwen Wang

Beijing Chaoyang Hospital, Capital Medical University

wjianw99@sina.cn+86 13910818269

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026